14 April 2023
Craneware plc
("Craneware" or the "Company" or the "Group")
Block Listing Announcement
Schedule 6, Block Admission Period to 14 April 2023
This block admission announcement, as required by the AIM Rules, is made every six months and relates to the number of shares that have been issued and allotted during this six month period under the Company's block listing for employee share plans.
Name of the company
Craneware plc (the "Company")
Names of the schemes
Approved Share Option Plan 2007
Schedule 4 Company Share Option Plan 2016
Unapproved Company Share Option Plan 2016
Long Term Incentive Plan 2016
SAYE Option Plan 2018
Employee Stock Purchase Plan 2018
Period of return:
15/10/2022 to 14/04/2023
Balance of unallotted securities under scheme(s) from previous return:
Approved Share Option Plan 2007:
342,301 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares")
Schedule 4 Company Share Option Plan 2016: 50,000 Ordinary Shares
Unapproved Company Share Option Plan 2016: 200,000 Ordinary Shares
Long Term Incentive Plan 2016: 100,000 Ordinary Shares
SAYE Option Plan 2018: 100,000 Ordinary Shares
Employee Stock Purchase Plan 2018: 84,370 Ordinary Shares
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
None
Less: Number of securities issued/allotted under scheme(s) during period:
None
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
Approved Share Option Plan 2007:
342,301 Ordinary Shares
Schedule 4 Company Share Option Plan 2016: 50,000 Ordinary Shares
Unapproved Company Share Option Plan 2016: 200,000 Ordinary Shares
Long Term Incentive Plan 2016: 100,000 Ordinary Shares
SAYE Option Plan 2018: 100,000 Ordinary Shares
Employee Stock Purchase Plan 2018: 84,370 Ordinary Shares
Number and class of securities originally admitted at the date of admission:
24,929,950 Ordinary Shares on 13 September 2007
Contact name and telephone number:
Craig Preston +44 (0) 131 550 3100
Enquiries:
Craneware plc |
+44 (0)131 550 3100 |
Keith Neilson, CEO |
|
Craig Preston, CFO |
|
Alma (Financial PR) |
+44 (0)20 3405 0205 |
Caroline Forde, Joe Pederzolli, Kinvara Verdon |
|
Peel Hunt (NOMAD and Joint Broker) |
+44 (0)20 7418 8900 |
Dan Webster, Andrew Clark, Lait Bose |
|
Investec Bank PLC (Joint Broker) |
+44 (0)20 7597 5970 |
Patrick Robb, Henry Reast, Sebastian Lawrence |
|
Berenberg (Joint Broker) |
+44 (0)20 3207 7800 |
Mark Whitmore, Richard Andrews, Dan Gee-Summons |
About Craneware
We at The Craneware Group of companies, including our latest additions Sentry Data Systems and Agilum Healthcare Intelligence, passionately believe we can impact healthcare profoundly by delivering the insights healthcare organisations need to also transform the business of healthcare. Our shared vision is to be the operational and financial partner for US healthcare providers.
Our combined suite of applications and industry-leading team of experts help our customers contextualise operational, financial, and clinical data, providing insights that clearly demonstrate what great looks like. These value cycle insights deliver revenue integrity and 340B compliance, as well as margin and operational intelligence - something no other single partner can provide.
Together, approximately 40% of registered US hospitals are now our customers, including more than 12,000 US hospitals, health systems and affiliated retail pharmacies and clinics. Our customers are operating with a financial impact of nearly half a trillion dollars. We have data sets from customers covering more than 165 million unique patients encounters.
Learn more at www.thecranewaregroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDBLRIJMJTMTMBBTJ
Supplied Euroland.com - Privacy Policy